Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 1/2016

01-02-2016 | Research Article

Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques

Authors: Petteri Rinne, Sanna Hellberg, Max Kiugel, Jenni Virta, Xiang-Guo Li, Meeri Käkelä, Kerttuli Helariutta, Pauliina Luoto, Heidi Liljenbäck, Harri Hakovirta, Maria Gardberg, Anu J. Airaksinen, Juhani Knuuti, Antti Saraste, Anne Roivainen

Published in: Molecular Imaging and Biology | Issue 1/2016

Login to get access

Abstract

Purpose

Rupture-prone atherosclerotic plaques are characterized by accumulation of macrophages, which have shown to express somatostatin type 2 receptors. We aimed to investigate whether somatostatin receptor-targeting positron emission tomography (PET) tracers, [68Ga]DOTANOC, [18F]FDR-NOC, and [68Ga]DOTATATE, can detect inflamed atherosclerotic plaques.

Procedures

Atherosclerotic IGF-II/LDLR−/−ApoB100/100 mice were studied in vivo and ex vivo for tracer uptake into atherosclerotic plaques. Furthermore, [68Ga]DOTANOC and [68Ga]DOTATATE were compared in a head-to-head setting for in vivo PET/X-ray computed tomography (CT) imaging characteristics.

Results

Ex vivo uptake of [68Ga]DOTANOC and [68Ga]DOTATATE in the aorta was higher in atherosclerotic mice compared to control C57Bl/6N mice, while the aortic uptake of [18F]FDR-NOC showed no genotype difference. Unlike [18F]FDR-NOC, [68Ga]DOTANOC and [68Ga]DOTATATE showed preferential binding to atherosclerotic plaques with plaque-to-wall ratio of 1.7 ± 0.3 and 2.1 ± 0.5, respectively. However, the aortic uptake and aorta-to-blood ratio of [68Ga]DOTANOC were higher compared to [68Ga]DOTATATE in in vivo PET/CT imaging.

Conclusion

Our results demonstrate superior applicability for [68Ga]DOTANOC and [68Ga]DOTATATE in the detection of atherosclerotic plaques compared to [18F]FDR-NOC.
Appendix
Available only for authorised users
Literature
1.
Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410–1422CrossRefPubMed
2.
Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–519CrossRefPubMed
3.
4.
5.
6.
Tarkin JM, Joshi FR, Rudd JH (2014) PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 11:443–457CrossRefPubMed
7.
Rudd JH, Narula J, Strauss HW et al (2010) Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol 55:2527–2535CrossRefPubMed
8.
Ogawa M, Ishino S, Mukai T et al (2004) 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 45:1245–1250PubMed
9.
Zhang Z, Machac J, Helft G et al (2006) Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med 6:3PubMedCentralCrossRefPubMed
10.
Tahara N, Kai H, Ishibashi M et al (2006) Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48:1825–1831CrossRefPubMed
11.
Aziz K, Berger K, Claycombe K et al (2008) Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation 117:2061–2070CrossRefPubMed
12.
Paulmier B, Duet M, Khayat R et al (2008) Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol 15:209–217CrossRefPubMed
13.
Buettner C, Rudd JH, Fayad ZA (2011) Determinants of FDG uptake in atherosclerosis. JACC Cardiovasc Imaging 4:1302–1304CrossRefPubMed
14.
Rominger A, Saam T, Vogl E et al (2010) In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med 51:193–197CrossRefPubMed
15.
Li X, Bauer W, Kreissl MC et al (2013) Specific somatostatin receptor II expression in arterial plaque: 68Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis 230:33–39CrossRefPubMed
16.
Li X, Samnick S, Lapa C et al (2012) 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with 18F-FDG, calcium burden and risk factors. EJNMMI Res 2:52PubMedCentralCrossRefPubMed
17.
Wild D, Mäcke HR, Waser B et al (2005) 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32:724CrossRefPubMed
18.
Wild D, Schmitt JS, Ginj M et al (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30:1338–1347CrossRefPubMed
19.
Kiviniemi A, Gardberg M, Autio A et al (2014) Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies. Acta Oncol 53:1125–1134CrossRefPubMed
20.
Heinonen SE, Leppänen P, Kholová I et al (2007) Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ Res 101:1058–1067CrossRefPubMed
21.
Silvola JM, Saraste A, Laitinen I et al (2011) Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging 4:1294–1301CrossRefPubMed
22.
Körner M, Waser B, Schonbrunn A et al (2012) Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36:242–252PubMedCentralCrossRefPubMed
23.
Belosi F, Cicoria G, Lodi F et al (2013) Generator breakthrough and radionuclidic purification in automated synthesis of 68Ga-DOTANOC. Curr Radiopharm 6:72–77CrossRefPubMed
24.
Li XG, Autio A, Ahtinen H et al (2013) Translating the concept of peptide labeling with 5-deoxy-5-[18F]fluororibose into preclinical practice: 18F-labeling of Siglec-9 peptide for PET imaging of inflammation. Chem Commun (Camb) 49:3682–3684CrossRef
25.
Li XG, Helariutta K, Roivainen A et al (2014) Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography. Nat Protoc 9:138–145CrossRefPubMed
26.
Rinne P, Silvola JM, Hellberg S et al (2014) Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice. Arterioscler Thromb Vasc Biol 34:1346–1354CrossRefPubMed
27.
28.
29.
Adams RL, Adams IP, Lindow SW et al (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493–1498PubMedCentralCrossRefPubMed
30.
Armani C, Catalani E, Balbarini A et al (2007) Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol 81:845–855CrossRefPubMed
31.
Schatka I, Wollenweber T, Haense C et al (2013) Peptide receptor-targeted radionuclide therapy alters inflammation in atherosclerotic plaques. J Am Coll Cardiol 62:2344–2345CrossRefPubMed
32.
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214CrossRefPubMed
33.
Schuett H, Oestreich R, Waetzig GH et al (2012) Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32:281–290CrossRefPubMed
34.
35.
Wallace AM, McMahon AD, Packard CJ et al (2001) Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104:3052–3056CrossRefPubMed
36.
37.
Ducimetiere P, Eschwege E, Papoz L et al (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19:205–210CrossRefPubMed
38.
Metadata
Title
Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques
Authors
Petteri Rinne
Sanna Hellberg
Max Kiugel
Jenni Virta
Xiang-Guo Li
Meeri Käkelä
Kerttuli Helariutta
Pauliina Luoto
Heidi Liljenbäck
Harri Hakovirta
Maria Gardberg
Anu J. Airaksinen
Juhani Knuuti
Antti Saraste
Anne Roivainen
Publication date
01-02-2016
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 1/2016
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-015-0873-1

Other articles of this Issue 1/2016

Molecular Imaging and Biology 1/2016 Go to the issue

Brief Article

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer

Research Article

In Vivo Detection of miRNA Expression in Tumors Using an Activatable Nanosensor

Research Article

Non-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin

Research Article

Quantification of Dynamic [18F]FDG Pet Studies in Acute Lung Injury

Research Article

Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging

Research Article

MRI of High-Glucose Metabolism Tumors: a Study in Cells and Mice with 2-DG-Modified Superparamagnetic Iron Oxide Nanoparticles